MENLO PARK, Calif., March 6, 2018 – Adicet Bio, Inc. (“Adicet”), a biopharmaceutical company focused on the development of next-generation cell immunotherapies, announced today that Aya Jakobovits, Ph.D., Founder of Adicet Bio, has retired from her position as President and Chief Executive Officer. Dr. Jakobovits will continue to serve on Adicet's Board of Directors and act as a Senior Strategic Advisor to the company. Donald Santel, Executive Chairman of Adicet Bio, will serve as interim CEO while a search is being conducted.

“We are grateful for Aya’s vision and leadership in initiating and growing Adicet’s operations and activities and establishing Adicet’s cutting-edge allogeneic cell-based technologies,” said Donald Santel, Executive Chairman of Adicet Bio. “We will continue to benefit from her extensive experience in the development of immune-oncology products as well as her strategic advice and guidance as we advance Adicet's cell products forward.”

Dr. Jakobovits founded Adicet with OrbiMed in 2014 and led its operations since its inception. Under her leadership, Adicet closed a $51 million financing, developed a novel, proprietary allogeneic T-cell platform based on gamma-delta T-cells, complemented by differentiating capabilities to identify and direct T-cells to novel MHC-peptide targets through the acquisition of Applied Immune Therapies, Ltd. In addition, she established a broad collaboration with Regeneron Pharmaceuticals for the development of engineered immune cell therapeutics.

“I am proud of the accomplishments made by the Adicet team during my tenure,” said Dr. Jakobovits. “I am confident in the ability of the team to realize the full potential of our platform technologies and progress our product pipeline to clinical development. I am committed to continuing to provide advice and support."

About Adicet Bio, Inc.

Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies for cancer and other disease indications, with a focus on novel universal immune cell therapies (uICT) based on different subtypes of gamma delta T-cells. In August 2016, Adicet entered a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet uICT platform technology. Adicet's wholly owned subsidiary, Adicet Bio Israel, Ltd. is developing immunotherapies directed to the disease-specific peptide-MHC complexes associated with different disease indications. Adicet Bio was named by FierceBiotech to its “Fierce 15” Biotech Companies of 2016. Adicet Bio is located in Menlo Park, California. For more information, please visit our website at http://www.adicetbio.com.

Contact:

Donald Santel
dsantel@adicetbio.com

Adicet Bio, Inc.
200 Constitution Drive
Menlo Park, CA 94025
Ph: 650-338-0303